Attorneys Trial Group.com

FDA Report

In 2004, several high-profile drug safety cases raised concerns about the Food and Drug Administration's (FDA) ability to manage postmarket drug safety issues. In some cases there have been disagreements within FDA about how to address safety issues. In this report GAO (1) describes FDA's organizational structure and process for postmarket drug safety decision making, (2) assesses the effectiveness of FDA's postmarket drug safety decision-making process, and (3) assesses the steps FDA is taking to improve postmarket drug safety decision making. GAO conducted an organizational review and case studies of four drugs with safety issues: Arava, Rezulin, Bextra, and Propulsid.

To Read the Entire GAO Report, click here [PDF]

Report Highlights  |  Report Abstract

News Alert

FDA's drug safety process needs more work - GAO report
Food Consumer, IL - Apr 24, 2006
... In this report GAO (1) describes FDA's organizational structure and process for postmarket drug safety decision making, (2) assesses the effectiveness of FDA's ...

Report: FDA drug safety tools lacking
Chicago Tribune, United States - Apr 24, 2006
... In preparing their report, GAO investigators interviewed FDA scientists and managers and reviewed documents usually not provided to the public. ...

Hinchey: GAO report confirms FDA needs to be overhauled
WSTM-TV, NY - Apr 25, 2006
... an Ulster County Democrat -- says the Government Accountability Office report details problems ... told a Binghamton radio station (WNBF) that the FDA has long ...

Report faults FDA drug-safety unit
Boston Globe, United States - Apr 25, 2006
... US Representative Rosa DeLauro, a Connecticut Democrat on a House subcommittee with jurisdiction over the FDA, said. She said she hopes the GAO report will get ...

Report: FDA slow to address drug safety
Concord Monitor, NH - Apr 24, 2006
... Alastair Wood of Vanderbilt University, a prominent voice on on the FDA's advisory panel on drug safety and risk management, said the GAO report "confirmed a ...

Digitek Alert

Actavis, maker of the prescription drug DIGITEK, launched a Class I nationwide recall of the drug in April 2008. Digitek pills were made for an unknown period of time with a potentially fatal defect. Some tablets may have been twice as thick as they were supposed to be. That meant they could contain twice the approved level of Digitalis, the active ingredient in Digitek, leading to Digitalis toxicity. Read More

Florida Supreme Court Patient Ruling

The Florida Supreme Court rules that patients have a right to check records of past errors made by doctors and hospitals. The hospitals and doctors have been reluctant to produce records of past errors, but the Court ruled that voters adopted a "Patient's Right To Know" in November 2004. Read More

Man Says Paramedics' Mistake Broke His Spine, Shoulders

November 28, 2007: WFTV reports that AttorneysTrialGroup.com is representing an Orange County, FL man who was injured when paramedics attempted to transport him to the hospital for a diabetic emergency. Astolfo Lugo, Sr. broke his hip, both of his shoulders and suffered spinal fractures. Read More

Read the full article at WFTV.com.

Merck & Co to pay $4.85 billion

November 9, 2007: Merck & Co agreed to pay $4.85 billion to settle claims that its painkiller Vioxx caused heart attacks and strokes. Vioxx was prescribed to 80 million patients from May 1999 to September 2004, when it was voluntarily recalled by Merck. Following the recall, suits were filed on behalf of 47,000 claimants across the US. "Great news," exclaims Attorney Carlos Diez-Arguelles. Read More

Medical Malpractice caps ruled unconstitutional

October 30, 2007: the Ninth Judicial Circuit Court of Orange County, FL ruled that medical malpractice caps on award damages are unconstitutional. A statute enacted in 2003 provided caps on damages. The Court ruled that this statute is contradicted by the Florida Constitution, Article I, Section 26 that was made part of the State Constitution by Florida voters in November 2004. Read More